Launch
With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
BioPharma Dive · By Ben Fidler ·
The Brief
- The FDA has approved Livsayis, Regeneron's first marketed RNAi drug, for an autoimmune disease.
- Livsayis is the product of a collaboration between Regeneron and Alnylam.
- It will compete with established autoimmune medicines from AstraZeneca and Argenx.
Why it matters
It is a new approved drug built on RNA interference, a gene-silencing approach, and it adds a competitor in the autoimmune treatment market.
Who’s affected
- patients with autoimmune disease
- researchers and clinicians working on RNA interference therapies
- pharmaceutical industry analysts
- #rna interference
- #drug approval
- #autoimmune disease
- #fda
- #regeneron
The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.